Lancet HIV Cohort Confirms TB Preventive Treatment Cuts Incidence and Mortality in Routine HIV Programs Across Six Nations

The PROTECT study analyzed routine data from PEPFAR-supported HIV clinics after the 2018 scale-up that delivered TPT to more than 13 million people. Researchers compared outcomes among those who received TPT versus those who did not, adjusting for CD4 count, ART status, and country-level TB burden. TB incidence fell and survival improved across risk strata, with strongest effects when treatment began early in HIV care. The design captured implementation realities absent from prior trials, including variable adherence and health-system constraints.

These results align with earlier trial meta-analyses yet add external validity by using programmatic cohorts rather than selected participants. Observational data from similar PEPFAR expansions in sub-Saharan Africa had already hinted at mortality reductions, but lacked the multi-country prospective structure and meta-analytic pooling performed here. Funding disruptions noted in the source threaten continuation; historical pauses in global TB funding have previously produced measurable rises in incidence within two years.

The study cannot establish causality as definitively as an RCT and leaves open questions about optimal shorter regimens and integration with newer ART formulations. Next required evidence includes randomized implementation trials comparing 1-month and 3-month regimens head-to-head in the same program settings, plus cost-effectiveness analyses tied to current funding levels.

Evidence quality note: prospective cohort with meta-analysis can demonstrate association and real-world effectiveness but cannot rule out residual confounding; a large pragmatic RCT is needed to confirm effect sizes under current resource constraints.